I'm LongbridgeAI, I can summarize articles.Esperion Therapeutics completed its merger, implementing a $100M Contingent Value Rights (CVR) plan for milestone payments. The company amended its 2030 convertible notes to reflect post-merger conversion terms in cash and CVRs. Additionally, Esperion secured new debt financing from BioPharma Credit to fund the transaction and terminated its existing 2024 credit facility.
Esperion Therapeutics finalized a series of agreements tied to the completion of its merger, including a Contingent Value Rights (CVR) Agreement offering up to $100 million in potential milestone payments. The company also executed a Second Supplemental Indenture for its 5.75% convertible notes due 2030, setting post-merger conversion economics in cash and CVRs, including enhanced make-whole terms. In parallel, Esperion entered into a new loan agreement led by BioPharma Credit to fund the cash consideration and related needs, and repaid and terminated its 2024 credit facility. Together, these steps align capital structure and investor incentives with the company’s post-merger outlook.
Agreement 1: Esperion Therapeutics Implements CVR Agreement Tied to Merger, Up to $100 Million Milestones
- Agreement type: Contingent Value Rights Agreement
- Counterparty: Essence Parent; Computershare (Rights Agent)
- Signed / Effective: Jul 13 2026 / Jul 13 2026
- Duration / Termination: Milestone periods per agreement
- Reason: Implement merger consideration with contingent payouts
Agreement 2: Esperion Therapeutics Amends 2030 Convertible Notes Terms After Merger; Cash and CVR Conversion Set
- Agreement type: Second Supplemental Indenture for 5.75% Convertible Senior Subordinated Notes due 2030
- Counterparty: Essence Parent; U.S. Bank Trust Company (Trustee)
- Signed / Effective: Jul 13 2026 / Jul 13 2026
- Duration / Termination: Until 2030 maturity
- Reason: Align convertible notes with merger terms
Agreement 3: Esperion Therapeutics Secures New Debt Financing With BioPharma Credit to Support Merger
- Agreement type: Loan agreement for merger financing
- Counterparty: BioPharma Credit; BPCR; BioPharma Credit Investments V (Master)
- Signed / Effective: Jul 13 2026 / Jul 13 2026
- Reason: Finance acquisition and refinance prior debt
Agreement 4: Esperion Therapeutics Retires 2024 Credit Agreement After Merger; Facility Repaid and Terminated
- Agreement terminated: Credit Agreement
- Counterparty: GLAS USA; GLAS Americas; lenders and issuing banks
- Original agreement date: Dec 13 2024
- Termination date: Jul 13 2026
- Termination type: Early
- Reason: Refinance with new loan and consummation of merger
Original SEC Filing: Esperion Therapeutics, Inc. [ ESPR ] - 8-K - Jul. 13, 2026